RxDoctor Payments Data

G Figueira, MD

Internal Medicine · Delray Beach, FLNPI 1265465546

Payments from drug & device makers

$1,489in general payments, 2019–2025

Across 51 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$201
  • Stryker$179
  • Abbott$148
  • Bayer$125
  • Pfizer$113
  • Edwards Lifesciences$101
  • plus $622 from 15 others

What the payments were for

  • Food & beverage$1,489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,489 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$395,001
Medicare patients
1,118
Services billed
5,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$116,751
EliquisApixaban75$106,762
MounjaroTirzepatide42$65,239
JardianceEmpagliflozin38$54,387
XareltoRivaroxaban36$42,112
JanuviaSitagliptin Phosphate15$17,277
LinzessLinaclotide11$17,158
MyrbetriqMirabegron15$17,007
TrulicityDulaglutide11$15,954
SynthroidLevothyroxine Sodium123$9,236
Rosuvastatin Calcium626$7,954
Atorvastatin Calcium801$7,224
Levothyroxine Sodium596$7,147
Arnuity ElliptaFluticasone Furoate20$6,306
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$106,76275 claims
Lilly USA, LLCMounjaro, Trulicity$49$81,19353 claims
AbbVieLinzess, Synthroid$69$26,395134 claims
MerckJanuvia$20$17,27715 claims
Astellas Pharma US IncMyrbetriq$59$17,00715 claims
GSKArnuity Ellipta, Anoro Ellipta$14$11,14232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →